Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CCND3 | P30281 | 1/20 | 0.30 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 3/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25274709 | 0.77 | CHRM5 (0.42) | — | |
| SCHEMBL2883668 | 0.76 | HSD11B1 (0.40) | — | |
| SCHEMBL2882939 | 0.74 | OPRL1 (0.42) | GRM5PROKR1 | |
| SCHEMBL2882937 | 0.74 | OPRL1 (0.42) | GRM5PROKR1 | |
| SCHEMBL22635769 | 0.73 | IDO1 (0.52) | — | |
| SCHEMBL2881953 | 0.71 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL2877489 | 0.70 | SMN1; SMN2 (0.46) | GRIN2BPIK3CD | |
| SCHEMBL25723343 | 0.65 | CHRM5 (0.41) | PIK3CD | |
| SCHEMBL25723342 | 0.65 | CHRM5 (0.41) | PIK3CD | |
| SCHEMBL3701009 | 0.64 | TACR1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | TRPC6 442/4885GRIN2B 134/4885GRM5 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.